Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women aged 18 or older who have been diagnosed with endometrial cancer (specifically endometrioid or serous types) that has come back or continued to grow, regardless of what stage it was when first diagnosed
• People who have already had surgery to remove the uterus (hysterectomy) as part of their cancer treatment
• People whose cancer has continued to grow or spread during or after their most recent cancer treatment, which must have included platinum-based chemotherapy; if immunotherapy was considered an appropriate treatment option by their doctors, it must also have been given
• People who have received no more than three prior rounds (lines) of cancer treatment
• People whose tumour tests positive for a protein called nectin-4, based on a laboratory test of tumour tissue
• People whose side effects from previous treatments have mostly resolved, leaving only mild or no ongoing symptoms
• People who are in generally good physical condition and able to carry out normal daily activities with little or no limitation (based on a standard medical scoring system called ECOG, at level 0 or 1)
• People who have at least one measurable area of cancer that can be tracked on CT or MRI scans, meeting specific size requirements (confirm with trial site for exact measurements)
• People who have had their tumour tested for specific genetic markers related to DNA repair (called MSI and MMR status)
• People who, in their doctor's opinion, are expected to live at least 12 weeks and are well enough to receive an experimental treatment
• People whose blood, kidney, and liver function results meet specific minimum levels set by the trial (confirm with trial site for exact values)
• People who are able to understand and willing to sign a written consent form
• People who meet the trial's pregnancy prevention requirements — this includes being post-menopausal for at least one year, having had a surgical procedure that prevents pregnancy, or agreeing to use two effective methods of contraception from the time of signing the consent form until three months after the last dose of the study drug; abstinence is only accepted if it is consistent with the person's usual lifestyle (note: methods such as calendar-based or withdrawal methods are not considered acceptable)

Who may not be able to join:

• People diagnosed with a type of uterine cancer called endometrial sarcoma (including leiomyosarcoma, endometrial stromal sarcoma, or high-grade sarcoma)
• People whose endometrial cancer is not of the endometrioid or serous type; mixed tumours that involve other tissue types are also not eligible
• People whose tumour tissue does not show the nectin-4 protein in laboratory testing
• People who currently have brain or spinal fluid involvement from their cancer that is causing symptoms; people with brain metastases must have been treated and been stable for at least four weeks before joining
• People who have been treated for another active cancer within the past 24 months (some exceptions may apply, such as certain skin cancers or early-stage cancers treated with local procedures — confirm with trial site)
• People experiencing moderate to severe nerve damage affecting sensation or movement (grade 2 or higher neuropathy)
• People who have had a significant heart or blood vessel problem within the past 12 months, such as heart failure, unstable chest pain, a heart attack, stroke, or a serious abnormal heart rhythm
• People who have required antibiotic treatment through a drip (IV) within the past 14 days, or antibiotic tablets within the past 7 days, for an active infection (routine treatment for urinary tract infections may be an exception — confirm with trial site)
• People with poorly controlled diabetes, indicated by a blood sugar marker (HbA1c) of 8% or above
• People with active Hepatitis B, Hepatitis C, or HIV infection
• People who have not yet recovered from significant side effects of previous cancer treatments or major surgery (some exceptions may apply for certain nerve-related or hormone-related side effects — confirm with trial site)
• People who are currently receiving cancer treatment, including chemotherapy, radiation, hormone therapy, immunotherapy, or another trial treatment, unless it was stopped at least four weeks before joining the study and there are no plans to restart it
• People who currently have a blocked bowel (intestinal obstruction)
• People with a known mental health condition or substance use disorder that would make it difficult to follow the trial requirements
• People who have taken immune-suppressing medications above a certain dose within seven days before the first dose of the study drug
• People who are pregnant or currently breastfeeding
• People whom the trial doctor believes, for any reason, may not be suitable for the full duration of the study or for whom participation may not be in their best interest

Important: Always verify eligibility with the trial site directly before applying.